Drugs For The Heart

The new 6th Edition continues to be the definitive pocket-sized guide on the "hows" and "whys" of cardiovascular drugs. It provides in-depth information on all of the drug classes used to treat heart disease, and covers drug use, new drug classes, drug use for single and multiple problem management, and more. A user-friendly organization speed readers to the information they need, and dynamic new full-color drawings illustrate key pharmacological and physiological actions. The new edition includes access to the companion website, which offers bi-annual content updates to keep you current with new drugs, indications and leading trials. The website also has the feature of fully searchable text to access book content via drug, disease or drug action.

Authoritative, portable, and up to date, Opie’s Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format—ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease. Uses a new, consistent format for each drug class: overview and guidelines for use, mechanisms of action, differences among drugs in class, data for use, side effects, and drug interactions. Covers key topics such as new ESC and NLA guidelines, advances in lipid-lowering therapy, new diabetes drugs that improve cardiovascular outcomes, obesity drugs and cardiovascular and metabolic effects, drugs targeting inflammation, and combinations of antithrombotic therapies with analysis of risk-benefit. Provides guidance on how to effectively manage comorbid diseases. Contains dozens of unique “Opiegram diagrams that demystify complex mechanisms of action and other drug processes—many updated to reflect current pathologic understanding of mechanisms.

Drugs for the Heart presents highly portable, up-to-date information on every drug class used to treat cardiovascular disease. Drs. Lionel H. Opie and Bernard J. Gersh put the latest dosages, interactions, indications and contraindications, side effects, and more at your fingertips, equipping you to make effective clinical decisions on behalf of your patients. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Quickly check when to use each drug for any condition with the popular "Which Drug for Which Disease" chapter. Get expert advice from the practice-proven experience of two well-known editors who represent the best possible combination of clinical and research expertise in cardiovascular therapeutics. Expedite your reference with summaries of each drug class at the end of chapters. Carry it with you anywhere thanks to a highly compact, pocket-sized format. Navigate the latest pharmacologic advances through coverage of the newest drugs and drug classes, as well as all the latest clinical trial results and evidence used to treat heart disease. Effectively manage comorbid diseases. Apply international insights into cardiac drugs, thanks to new global contributors. Visualize key pharmacologic and physiologic actions thanks to dynamic new full-color drawings. Access the complete contents online at Expert Consult, with regular online updates posted by leading cardiologist, Dr. Opie.

The notion that drugs can induce valvular heart disease (VHD) has occurred since the sixties and has received a lot of attention in recent years. Overstimulation of the serotonin 2B receptor (5-HT2B) leads to valvular fibroblast proliferation and thickening of the valvular leaflets with reduced mobility and regurgitation as a consequence. This new book focuses on different aspects of this distinct kind of valvulopathy including pathophysiology of drug-induced VHD, histopathological and echocardiographic characteristics, drugs associated with VHD, the influence of cumulative drug dose and risk factors and others.

"EACPR, European Association for Cardiovascular Prevention and Rehabilitation -- European Society of Cardiology."

This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences.

This South Asia edition of the market-leading cardiac drug resource presents drug and disease scenarios apt for this region. It provides in-depth information on every drug class used to treat heart disease, including the popular "Which Drug for Which Disease" chapter - equipping readers to make effective clinical decisions.. Navigate the latest pharmacologic advances through coverage of the newest drugs and drug classes, as well as all the latest clinical trial results and evidence. . Effectively manage comorbid diseases. . Apply international insights-thanks to new global contributors. . Visualize key pharmacologic and physiologic actions-thanks to dynamic new full-color drawings.

The Heart and Toxins brings together global experts to provide the latest information and clinical trials that make the connection between genetic susceptibility, gene expression, and environmental factors in cardiovascular diseases. This unique reference, edited by renowned cardiologist Meenakshi Sundaram Ramachandran, solves the problem of managing multiple clinical cases of cardiovascular toxicity. It allows connections to be made between research, diagnosis, and treatment to avoid higher morbidity and mortality rates as a result of cardiovascular toxicity. Structured to bring together exploration into the epidemiology, molecular mechanism, pathogenesis, environmental factors and management in cardiovascular toxins” Included various topics on cardiovascular toxins such as plant, chemical, animal, nanomaterial and marine biology induced cardiac damage – which are new ideas discussed in detail Comprehensive chapters on the cardiovascular toxicity from drugs, radiotherapy and radiological imaging Enables you to manage multiple clinical cases of cardiovascular toxicity Outlined conclusions at the end of each chapter providing “key learning points” to help you organize the chapter’s details without losing insight